Tariq Warsi
Senior Director at Neogene Therapeutics
Los Angeles Metropolitan Area
Overview
Work Experience
USC Alfred E. Mann Institute Investment Director
2025 - Current
• General Partner of the USC AMI Innovation Fund, deployment of evergreen endowed fund towards USC affiliated companies in Biomedical and Healthcare Innovation • Building the life science innovation ecosystem in Southern California to support startups, incubators, and accelerators
Entrepreneur in Residence
2023
Venture Partner
2023
Awaken Capital invests in tech-enabled platforms and the visionary entrepreneurs behind them at the early stages of their development.
Senior Director
2023 - 2025
• Overseeing process development activities for cell therapy modalities including autologous CAR-T, allogeneic, and TCR-T platforms and delivering a high-quality manufacturing process for multiple clinical stage programs • Managing a team of scientists, associates, contractors, and consultants across multiple sites • Authoring IND sections, responding to regulatory requests, and implementing a phase-appropriate approach to CMC life-cycle management • Successfully delivering milestones needed to satisfy an acquisition by a major pharmaceutical company
Independent Consultant
2023 - 2023
• Technical operations, process development, GMP, and CMC expert in multiple modalities including cell and gene therapies, live biotherapeutic products, biologics, DNA/RNA, etc. • Expertly trained in synthetic biology, cell and molecular biology, gene editing, genomics, and bioengineering • GMP, quality, and regulatory support of novel modalities for global regulatory agencies • Scientific advisor and board member offering support on research and development, technical strategy, business development, and financing • Venture partner providing due diligence on technical aspects in various biotech sectors • Entrepreneur in residence supporting technology transfer, part-time C-suite, academic/industry relationships, and early-stage company guidance
Vice President Technical Operations
2022 - 2023
• Leading multiple high-performance teams across Process Development, Manufacturing, Quality, CMC, and Clinical Supply for genetically modified cell therapies, and successfully delivering cGMP clinical drug product to Phase 1/2 subjects • Successfully overseeing the technology transfer and manufacturing of drug substance and drug products at CDMOs, with release of multiple batches of study product for clinical trials • Drafting and submission of IND modules, regulatory feedback, and technical documents; leading to an approved IND in a novel modality • Managing a budget to ensure company operations, delivery of high-quality drug product, and CDMO contract execution • Building teams and hiring core staff across functional areas and operations verticals
Head Of Technical Operations
2020 - 2022
Novome Biotechnologies is a biotechnology company focused on engineering defined activities into the human.
Raised $83,060,623.00 from 5AM Ventures, Alexandria Venture Investments, Alta Partners, Tencent, DCVC Bio, Touchdown Ventures, University of Minnesota and Navian Capital.
Vice President of Research and Development
2020 - 2020
• Leading programs in research and development, process development, quality control, and manufacturing to create a cell therapy and exosome platform for therapeutic indications in infectious disease, oncology, and inflammation
Capricor Therapeutics is a biotechnology company focusing on cell and exosome-based therapeutics.
Raised $179,500,504.00 from Nippon Shinyaku, Cedars Sinai, CureDuchenne Ventures, Broadview Ventures, Calmedica and Beechwood Ventures.
CEO and Co-founder
2018 - 2020
• Leading scientific efforts, fundraising, growth, budgets, and the overall strategy of the company • Developing a platform to enable the discovery of novel microbes associated with marine hosts • Development of bioactive compounds, protein, and specialty chemicals in novel marine microbes
Operations Lead, Cell and Gene Therapy
2018 - 2020
• Process Development and CMC lead for live cell modalities including CAR T-cell therapies, neoantigen immunotherapy, and gene editing • Project Team Lead (PTL) for TCR-T cell therapy programs, Attribute Sciences Team Lead (ASTL) for CAR-T cell therapy program, Early Operations Lead (EOL) for neoantigen immunotherapy program
Senior Scientist
2015 - 2018
• Managing a team composed of PhD scientists, associate scientists, and senior associates to develop and execute bioassay, immunoassay, and molecular assays for release of large molecule therapeutics
Amgen is a biotechnology company that develops and manufactures human therapeutics for various illnesses and diseases.
Raised $28,500,000,000.00 from Citibank and Bank of America.
Education
Postdoctoral Fellow
2009 - 2011
PhD
2002 - 2009
BS
1998 - 2002